Literature DB >> 16987826

Immunological basis of systemic sclerosis.

J-P Zuber1, F Spertini.   

Abstract

Systemic sclerosis (SSc) is a disease of unknown aetiology characterized by excessive and often progressive fibrosis in skin and multiple internal organs, an aberrant immune activation marked by multiple humoral and cellular immunological abnormalities and pronounced alterations in the microvasculature. The pathogenesis of SSc is complex and, although progress in the understanding of the multiple processes underlying SSc has been made in recent years, no single unifying hypothesis explaining all aspects of this disease exists. Recent studies have suggested that the activation of the immune system is a key stimulus to vascular abnormalities and fibrosis. Once T-cells are activated, they infiltrate the skin lesions early, and produce the profibrotic cytokine IL-4. They are also required for autoantibody production. B-cells may contribute to fibrosis, as deficiency of CD19, a B-cell signal transduction molecule, results in decreased fibrosis in animal models. In recent years, clinical advances have occurred in parallel with a better understanding of the underlying disease mechanisms. In this article, the immunological aspects and multiple altered immunological processes found in SSc are discussed.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16987826     DOI: 10.1093/rheumatology/kel285

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  13 in total

1.  [Systemic sclerosis--a challenge in rheumatology].

Authors:  P Saar; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

2.  [Gastrointestinal involvement in systemic sclerosis. An underestimated complication].

Authors:  P Saar; T Schmeiser; I H Tarner; U Müller-Ladner
Journal:  Hautarzt       Date:  2007-10       Impact factor: 0.751

Review 3.  Fibrosis--a lethal component of systemic sclerosis.

Authors:  Yuen Yee Ho; David Lagares; Andrew M Tager; Mohit Kapoor
Journal:  Nat Rev Rheumatol       Date:  2014-04-22       Impact factor: 20.543

Review 4.  Interleukin 4: Its Role in Hypertension, Atherosclerosis, Valvular, and Nonvalvular Cardiovascular Diseases.

Authors:  Kamal M Kassem; Mahboob Ali; Nour-Eddine Rhaleb
Journal:  J Cardiovasc Pharmacol Ther       Date:  2019-08-11       Impact factor: 2.457

5.  Profibrotic Role for Interleukin-4 in Cardiac Remodeling and Dysfunction.

Authors:  Hongmei Peng; Zeyd Sarwar; Xiao-Ping Yang; Edward L Peterson; Jiang Xu; Branislava Janic; Nadia Rhaleb; Oscar A Carretero; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2015-07-20       Impact factor: 10.190

Review 6.  The Pathophysiological Roles of Regulatory T Cells in the Early Phase of Systemic Sclerosis.

Authors:  Satomi Kobayashi; Yasuo Nagafuchi; Hirofumi Shoda; Keishi Fujio
Journal:  Front Immunol       Date:  2022-05-24       Impact factor: 8.786

7.  All-Trans Retinoic Acid Induces CD4+CD25+FOXP3+ Regulatory T Cells by Increasing FOXP3 Demethylation in Systemic Sclerosis CD4+ T Cells.

Authors:  Xiaohong Sun; Yangfan Xiao; Zhuotong Zeng; Yaqian Shi; Bingsi Tang; Hai Long; Takuro Kanekura; Jiucun Wang; Haijing Wu; Ming Zhao; Qianjin Lu; Rong Xiao
Journal:  J Immunol Res       Date:  2018-04-30       Impact factor: 4.818

8.  Elevated levels of CD4(+)CD25(+)FoxP3(+) T cells in systemic sclerosis patients contribute to the secretion of IL-17 and immunosuppression dysfunction.

Authors:  Xinjuan Liu; Na Gao; Mengtao Li; Dong Xu; Yong Hou; Qian Wang; Guohua Zhang; Qiuning Sun; Henghui Zhang; Xiaofeng Zeng
Journal:  PLoS One       Date:  2013-06-11       Impact factor: 3.240

9.  Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.

Authors:  Elena Schiopu; Soumya Chatterjee; Vivien Hsu; Armando Flor; Daniel Cimbora; Kaushik Patra; Wenliang Yao; Jing Li; Katie Streicher; Kathleen McKeever; Barbara White; Eliezer Katz; Jorn Drappa; Sarah Sweeny; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2016-06-07       Impact factor: 5.156

10.  Fibrosis Development in HOCl-Induced Systemic Sclerosis: A Multistage Process Hampered by Mesenchymal Stem Cells.

Authors:  Alexandre T J Maria; Karine Toupet; Marie Maumus; Pauline Rozier; Marie-Catherine Vozenin; Alain Le Quellec; Christian Jorgensen; Danièle Noël; Philippe Guilpain
Journal:  Front Immunol       Date:  2018-11-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.